"Multicenter, prospective, open label study , in patients with non small cell lung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of first line chemotherapy in which it's possible a treatment that evaluates the effectiveness and the safety of oral BIBF 1120 in combination with standard docetaxel therapy, which can be administered (at the discretion of the referring physician) with tri-weekly or weekly schedule

Trial Profile

"Multicenter, prospective, open label study , in patients with non small cell lung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of first line chemotherapy in which it's possible a treatment that evaluates the effectiveness and the safety of oral BIBF 1120 in combination with standard docetaxel therapy, which can be administered (at the discretion of the referring physician) with tri-weekly or weekly schedule

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2015

At a glance

  • Drugs Nintedanib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SENECA
  • Most Recent Events

    • 16 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top